Health · NASDAQ · USD · Data as of 2026-05-12
AUM
$57.69M
Expense ratio
0.50%
Yield
0.39%
YTD return
-8.36%
Last price
$24.33
Thematic Sector · Coverage 75% · low
Today
27.7
Outlook
48.6
Block A (composite-derived)
60.2
Block C (market behavior)
10.2
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
60.2
Coverage 75% · medium
Liquidity
—
Expenses
65.0
Performance
—
Volatility
44.1
Dividend
19.6
Concentration
70.0
Smart Money
68.3
Activist
100.0
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund from Fidelity Investments in the Mixed asset class. Launched in 2020. Assets under management: 57,694,524.
Bullish Whales composite rating: 60 out of 100. Evidence coverage 75% across 6 of 8 axes. Strongest axes: activist exposure, concentration, smart-money flow.
Annualized one-year realized volatility 19%, classified moderate. Weakest axes: dividend, volatility.
Top-10 weight 0%, diversified, led by DHR. Trailing yield 0%.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, dividend_score, smart_money_score, volatility_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yThe Fidelity Disruptive Medicine ETF is an exchange-traded fund designed to provide exposure to companies that are on the cutting edge of medical innovation. This ETF focuses on businesses that are involved in the development and application of revolutionary medical technologies, which might include areas such as gene editing, biotechnology, pharmaceutical advancements, and medical devices. By concentrating on these sectors, the ETF aims to capture growth opportunities from companies that are transforming healthcare with new treatments and technologies. In doing so, it supports investors seeking to capitalize on significant developments in the healthcare space. The ETF's role in the market is to serve as a dynamic investment vehicle that reflects the rapid pace of change in the medical field, potentially offering portfolio diversification through exposure to emerging market trends in healthcare.
Net AUM change history is not yet available for this ETF. Fund-flow time series is a Phase B deliverable.
Current AUM: $57,694,524. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for FMED are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.